Promising results support global submissions and priority review by US FDA
News
Lilly’s Jaypirca shows positive results in phase 3 trial
Pirtobrutinib meets primary endpoint in CLL/SLL study
Lilly and UK Government launch £85 million obesity care innovation programme
Nationwide competition to pilot new models of obesity support
Sever Pharma expands work on ketamine implant with Silo Pharma
New phase of development targets chronic pain and fibromyalgia
Scotland approves zanubrutinib for relapsed mantle cell lymphoma
New treatment option now available across all UK nations
NICE backs KEYTRUDA combination for advanced endometrial cancer
New first-line option for patients with pMMR and dMMR tumours in England
FDA expands AVTOZMA IV approval to include cytokine release syndrome
Celltrion’s biosimilar now fully aligned with ACTEMRA IV indications in US
Nxera unveils proprietary pipeline targeting obesity and metabolic disorders
New oral GLP-1 agonist aims to reshape chronic weight management
Porosome Therapeutics unveils breakthrough Alzheimer’s research
FDA validation and AI-designed therapies mark major shift in treatment strategy
Bath researchers develop pill-based alternative to injections
New drug delivery system could transform treatment for chronic conditions
Gedeon Richter launches Nalvee in UK to expand HRT options for menopause
Dydrogesterone-only tablet returns after 17-year absence to support personalised care
US$30.9 million strategic equity deal strengthens Everest’s oncology platform
US$30.9 million strategic equity deal strengthens oncology platform
Microbiotica completes recruitment for phase 1b ulcerative colitis trial
MB310 study investigates safety and efficacy of precision microbiome therapy
Eisai data shows sustained benefit of lecanemab in early Alzheimer’s disease
Four-year treatment slows cognitive decline with consistent safety profile
Moderna wins EU approval for updated COVID-19 vaccine
Spikevax authorised to target LP.8.1 variant ahead of 2025-2026 season
